Patents by Inventor Ryohei ISHIBA
Ryohei ISHIBA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944620Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: April 2, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938131Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-(3-methoxy-4-4-(4-methylpiperazin-1-yl)piperidin-1-yl phenylamino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938130Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938132Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Patent number: 11938133Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 12, 2023Date of Patent: March 26, 2024Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Publication number: 20230310422Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 5, 2023Publication date: October 5, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230301992Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 28, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277531Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277529Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277530Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230277532Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 12, 2023Publication date: September 7, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20230129146Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 21, 2022Publication date: April 27, 2023Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Publication number: 20200383977Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-4[-4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 24, 2020Publication date: December 10, 2020Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Patent number: 10786500Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 1, 2016Date of Patent: September 29, 2020Assignee: ASTELLAS PHARMA INC.Inventors: Masakazu Miyazaki, Ryohei Ishiba, Yuki Takaishi, Fumiaki Uejo
-
Publication number: 20180185359Abstract: Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound A) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound A or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound A or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 1, 2016Publication date: July 5, 2018Applicant: ASTELLAS PHARMA INC.Inventors: Masakazu MIYAZAKI, Ryohei ISHIBA, Yuki TAKAISHI, Fumiaki UEJO
-
Patent number: 9708628Abstract: The present invention relates to a compound represented by the formula (1) wherein Xa and Xb are each independently X1 or X2; s is 1 or 2, R4 is an alkyl group having 1-6 carbon atoms, na and nb are each independently 0 or 1, R1a and R1b are each independently an alkylene group having 1-6 carbon atoms, R2a and R2b are each independently an alkylene group having 1-6 carbon atoms, Ya and Yb are each independently an ester bond, an amide bond, a carbamate bond, an ether bond or a urea bond, and R3a and R3b are each independently a sterol residue, a liposoluble vitamin residue or an aliphatic hydrocarbon group having 12-22 carbon atoms, and use thereof.Type: GrantFiled: May 16, 2014Date of Patent: July 18, 2017Assignees: NOF Corporation, National University Corporation Hokkaido UniversityInventors: Kota Tange, Masaya Arai, Kazuhiro Kubo, Hidetaka Akita, Hideyoshi Harashima, Hiroto Hatakeyama, Ryohei Ishiba, Masami Ukawa, Hiroki Tanaka
-
Publication number: 20140335157Abstract: The present invention relates to a compound represented by the formula (1) wherein Xa and Xb are each independently X1 or X2; s is 1 or 2, R4 is an alkyl group having 1-6 carbon atoms, na and nb are each independently 0 or 1, R1a and R1b are each independently an alkylene group having 1-6 carbon atoms, R2a and R2b are each independently an alkylene group having 1-6 carbon atoms, Ya and Yb are each independently an ester bond, an amide bond, a carbamate bond, an ether bond or a urea bond, and R3a and R3b are each independently a sterol residue, a liposoluble vitamin residue or an aliphatic hydrocarbon group having 12-22 carbon atoms, and use thereof.Type: ApplicationFiled: May 16, 2014Publication date: November 13, 2014Inventors: Kota TANGE, Masaya ARAI, Kazuhiro KUBO, Hidetaka AKITA, Hideyoshi HARASHIMA, Hiroto HATAKEYAMA, Ryohei ISHIBA, Masami UKAWA, Hiroki TANAKA